Given that the number of patients with AD-DLB is greater than that of patients with AD-TDP43 in the cohort, we used the post-mortem brains of patients with AD-DLB for subsequent analysis to understand their biochemical and molecular heterogeneities, comparing AD-alone and normal controls. The gene discussed is TARDBP; the disease is Lewy body dementia.